

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)										ATTY. DOCKET NO. PC25339A		SERIAL NO. 10/734039			
										APPLICANT John C. Kath et al.					
										FILING DATE December 11, 2003		GROUP			
(s)	0	2	0	2	0	5	0	1	Mar 14, 02	WO					
(t)	0	2	0	0	8	1	9	3	Jan 31, 02	WO					
(u)	0	1	0	6	8	1	8	6	Sep 20, 01	WO					
(v)	0	1	0	2	1	5	9	7	Mar 29, 01	WO					
(w)	0	0	0	1	8	7	4	0	Apr 6, 00	WO					
(x)		9	9	0	9	0	1	6	Feb 25, 99	WO					
(y)		9	8	3	7	0	7	9	Aug 27, 98	WO					
(z)		9	8	0	9	9	6	1	Mar 12, 98	WO					
(aa)		9	8	0	5	6	6	1	Feb 12, 98	WO					
(bb)		9	7	1	2	8	8	0	Apr 10, 97	WO					
(cc)		9	3	2	4	4	6	7	Dec 9, 93	WO					
(dd)		9	3	1	0	0	8	6	May 27, 93	WO					
(ee)			5	5	3	0	1	6	July 5, 97	EP					
(ff)			5	4	2	0	7	9	July 23, 97	EP					
(gg)		4	0	2	9	6	5	0	Mar 26, 92	DE					
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)															
M		Search Report, 6/04/04, PCT/IB 03/05883													
M		Knockaert, Marie et al: "Identifying in vivo targets of cyclin-dependent kinase inhibitors by affinity chromatography" <u>Biochemical Pharmacology</u> (2002), 64 (5-6), 819-825, XP002274117													
M		Kath J C: "Patent Focus: Inhibitors of Tumour Cell Growth" <u>Expert Opinion on Therapeutic Patents</u> , Ashley Publications, GB, vol.10, no.6, 2000, pages 803-818, XP000919385 Issn: 1354-3776													
M		Stover D R et al: "Recent Advances in Protein Kinase Inhibition: Current Molecular Scaffolds Used for Inhibitor Synthesis" <u>Current Opinion in Drug Discovery and Development</u> , Current Drugs, London, GB, vol.2, no.4, 1999, pages 274-285, XP000926237 Issn: 1367-6733													
M		Bramson, H. Neal et al: "Oxindole-Based Inhibitors of Cyclin-Dependent Kinase 2 (CDK2): Design, Synthesis, Enzymatic Activities, and X-ray Crystallographic Analysis" <u>Journal of Medicinal Chemistry</u> (2001), 44(25), 4339-4358, XP002274118													
EXAMINER		V. Balasubramanian										DATE CONSIDERED		4/19/06	
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.															

Conforms with FORM PTO-FB-A820

INFORMATION DISCLOSURE

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)	ATTY. DOCKET NO. PC25339A	SERIAL NO. 10/734039
	APPLICANT John C. Kath et al.	
	FILING DATE December 11, 2003	GROUP

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER										DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
VB	(a)					5	5	2	1	1	8	4	May 28, 96	J. Zimmermann			
M	(b)					4	5	0	7	1	4	6	Mar 26, 85	H. Tobler			
M	(c)					5	8	6	3	9	2	4	Jan 26, 99	J. Berger			
M	(d)	2	0	0	3	0	1	6	2	8	0	2	Aug 28, 03	J. Guo			
M	(e)	2	0	0	3	0	1	8	1	4	7	4	Sep 25, 03	E. Pease			
CH	(f)	2	0	0	3	0	1	7	1	3	5	9	Sep 11, 03	G. Dahmann			
CH	(g)					6	2	9	7	2	5	8	Oct 2, 01	A. Wissner			
M	(h)					5	7	5	3	8	6	3	May 19, 98	L. Filppin			
CEP	(i)					4	9	8	3	6	0	8	Jan 8, 91	R. Effland			

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER										DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
														YES	NO
VB	(a)	0	3	0	3	2	9	9	7	Apr 24, 03	WO				
VB	(b)		9	7	1	9	0	6	5	May 29, 97	WO				
M	(c)		0	1	6	0	8	1	6	Aug 23, 01	WO				
M	(d)		0	0	3	9	1	0	1	July 6, 00	WO				
CH	(e)	0	2	0	9	6	8	8	7	Dec 5, 02	WO				
CH	(f)	0	2	0	9	6	8	8	8	Dec 5, 02	WO				
CH	(g)		0	2	1	6	3	4	8	Feb 28, 02	WO				
CH	(h)		0	2	1	6	3	5	2	Feb 28, 02	WO				
CH	(i)		0	2	1	2	2	2	7	Feb 14, 02	WO				
CH	(j)		0	2	1	2	2	2	8	Feb 14, 02	WO				
CH	(k)	0	3	0	9	5	4	4	8	Nov 20, 03	WO				
CH	(l)		0	1	7	2	7	4	4	Oct 4, 01	WO				
CH	(m)		9	9	4	1	2	5	3	Aug 19, 99	WO				
CH	(n)	0	3	0	7	8	4	0	4	Sept 25, 03	WO				
CH	(o)	0	3	0	3	0	9	0	9	April 12, 03	WO				
CH	(p)		0	3	1	8	0	2	1	March 6, 03	WO				
CH	(q)		0	3	6	3	7	9	4	Aug 7, 03	WO				
CH	(r)	0	3	0	6	6	5	7	5	Aug 14, 03	WO				

INFORMATION DISCLOSURE CITATION LIST.DOT, 3/99

V. Balasubramanian

11/19/08